麻豆传媒

Marjorie A. Speers, Ph.D., is a global leader in human research protections. Most recently, she was the inaugural president and CEO of the Association for the Accreditation of Human Research Protection Programs, Inc. (AAHRPP), retiring in 2013.

Dr. Speers views the opportunity to lead this one-of-a-kind foundation鈥攁nd continue to contribute to research protections and public well-being worldwide鈥攁s the natural progression in an exemplary career of public service. Before establishing AAHRPP in 2001, she served as acting executive director of the National Bioethics Advisory Commission. At the Centers for Disease Control and Prevention, she oversaw research protections for all domestic and international research.

Dr. Speers is a graduate of Dickinson College, where she serves on the Board of Trustees and established a scholarship that has benefited numerous international students. She also holds doctoral degrees in psychology and epidemiology from Yale University.

Raymond L. Woosley, MD, Ph.D., is a Flinn Scholar and professor of Biomedical Informatics and Medicine at the University of Arizona College of Medicine-Phoenix. He is also the founding president and chairman of the Board for AZCERT, Inc., a non-profit organization funded by the U.S. Food and Drug Administration to work with the College of Medicine to improve the safe use of medications.

Dr. Woosley received his medical degree from the University of Miami, FL; his doctorate in pharmacology from the University of Louisville, KY; and his bachelor's degree from Western Kentucky University. After an internship and residency in internal medicine, he completed a fellowship in clinical pharmacology at Vanderbilt University before joining the faculty as founding director of the Vanderbilt Cardiac Arrhythmia Center and rose to the rank of professor of Medicine and Pharmacology and associate director of the Vanderbilt Clinical Research Center.

In 1988, Dr. Woosley was appointed chairman of the Department of Pharmacology at Georgetown University Medical Center in Washington, D.C. He also served as associate dean for Clinical Research and director of the Institute for Cardiovascular Sciences. In 2001, Dr. Woosley joined the faculty at the University of Arizona as vice president of the Arizona Health Sciences Center and the dean of the College of Medicine. In 2005, he founded the Critical Path Institute (C-Path), an independent, non-profit organization created jointly by the U.S. Food and Drug Administration (FDA) and the University of Arizona to help implement the FDA鈥檚 Critical Path Initiative and accelerate the development of new drugs and diagnostics. In 2012, he founded the non-profit AZCERT, Inc.

Dr. Woosley鈥檚 research has been reported in more than 300 peer-reviewed publications and serves as the basis for eleven patents. For his contributions to medicine, Dr. Woosley has received numerous awards and honors from academic institutions, the Food and Drug Administration and professional societies.

Dr. Licciardone鈥檚 research focuses on the prevention and treatment of chronic pain. He is the first recipient of a Regents Professorship awarded by the Texas College of Osteopathic Medicine since it was established 50 years ago. He also holds the Osteopathic Heritage Foundation Distinguished Chair in Clinical Research in honor of Drs. David Richards and Benjamin Cohen, former President and Provost of the University of North Texas Health Science Center. He presently directs the Osteopathic Research Center, including its PRECISION Pain Research Registry. The latter is the 鈥渇irst-in-the-nation鈥� pain research registry, which studies precision medicine and biopsychosocial approaches to pain management. He received a Midcareer Investigator Award from the National Institutes of Health (NIH), served as an expert panelist for NIH in the area of chronic pain, and completed a four-year term on its National Advisory Council for Complementary and Integrative Health. He directed the OSTEOPATHIC Trial, a five-year study funded by NIH that demonstrated substantial improvements in and recovery from chronic low back pain with osteopathic manipulation. He is presently a Co-Investigator in the $14 million Prevention of Acute to Chronic Back Pain Trial (PACBACK Trial) sponsored by NIH, and recently served on the Work Group that developed NIH鈥檚 Federal Pain Research Strategy. Internationally, Dr. Licciardone has served as a consultant to the World Health Organization on regulatory and safety issues relating to osteopathy in Europe and other nations. He gave the keynote address at Advancing Osteopathy 2008, a conference celebrating the 10th anniversary of recognition of osteopaths in the United Kingdom鈥檚 National Health Service, including a preconference reception with His Royal Highness, The Prince of Wales. He has also met and advised two former United States Surgeons General on the role of osteopathic physicians within the American health care system. The American Osteopathic Foundation has honored Dr. Licciardone with its Gutensohn-Denslow Award for devoted lifetime service and contributions to research and education within the osteopathic profession. 

Associate Dean, Professor, and Department Chair of Clinical Research and Public Health at Creighton University鈥檚 School of Medicine
Dr. Maureen Tierney, M.D., M.S., is a distinguished researcher and renowned epidemiologist whose expertise covers several medical fields, including public health policy, infectious disease prevention, pathogen analysis, and health professions workplace safety.
Dr. Tierney earned the Inaugural McKnight Prize for Healthcare Outbreak Heroes in 2020 after her investigative work helped contain an infection outbreak in a hospital specialty unit. She is a member of the Infectious Disease Society of America, the Society for Healthcare Epidemiology of America, the Council of State and Territorial Epidemiologists, and the America College of Physicians. She has participated in CORHA (Council on Outbreak Response for Healthcare-Associated Infections and Antimicrobial Resistance). She has served previously as the Medical Director of the Healthcare-Associated Infections and Antimicrobial Resistance Program at Nebraska鈥檚 Department of Health and Human Services.
The principal investigator of a 2021 Centers for Disease Control-commissioned study on the impact of COVID, Dr. Tierney regularly publishes abstracts, articles, chapters, and regulatory documents to advise doctors, hospital administrators, and the general public.

An international leader in the clinical care of patients with breast cancer, Dr. Krop joined Yale from Dana-Farber Cancer Institute where he was the Associate Chief of the Division of Breast Oncology and an Associate Professor of Medicine at Harvard Medical School. Nationally, he serves as Chief Scientific Officer for the Translational Breast Cancer Research Consortium and the Co-Vice Chair for Correlative Science for the Alliance for Clinical Trials in Oncology. His research efforts have advanced the field through clinical trials that define the next generation of therapies for patients. Dr. Krop serves as a member of the NCI Breast Cancer Steering Committee and the Data Monitoring Committee for ECOG/ACRIN. He also serves on the Data and Safety Monitoring Boards for multiple phase III trials.

Education & Training:
PhD-Johns Hopkins University School of Medicine, Biochemistry, Cellular and Molecular Biology
MD-The Johns Hopkins University School of Medicine, Medicine

Dr. Rachel Freedman is a medical oncologist and clinical researcher at DFCI in the Breast Oncology Program.  In addition to seeing patients with breast cancer, her research focuses on improving the care of vulnerable patient populations who are under-represented in clinical trials and who are at risk for worse breast cancer outcomes, including older women and those who face challenges in access to care.  In addition, she is interested in novel therapeutics, serving as the Principal Investigator for several clinical trials.  She is also the founder and Director of the Program for Older Adults with Breast Cancer at DFCI.  Dr. Freedman joined the faculty at DFCI in 2009.  She studied at Georgetown University School of Medicine and obtained her master's in public health at the Harvard University T.H. Chan School of Public Health.  Her research has been funded by Susan G Komen, ACS, NCI, Gateway for Cancer Research, METAvivor, and the Alliance for Clinical Trials Foundation.

---